Codis to Acquire Catalent's Nottingham Facility, Pioneering Europe's Spray Drying Capabilities
In a significant move for the contract development and manufacturing organization (CDMO) sector, Codis has announced its plan to acquire Catalent Pharma Solutions' facility in Nottingham, UK. This acquisition marks a pivotal step in establishing Europe's premier end-to-end spray-drying capability. With the Nottingham site expected to bolster the development and production of solid oral dosage forms, Codis is set to transform the landscape of pharmaceutical manufacturing in Europe.
The Nottingham facility is well-regarded for its robust expertise in formulation development and scientific research, possessing over two decades of experience in providing successful spray-drying and oral solid dosage solutions. By integrating this facility into its operations, Codis aims to not only enhance its product offerings but also streamline its development-to-production processes, thereby positioning itself at the forefront of the rapidly evolving pharmaceutical landscape.
Nicolas Fortin, CEO of Codis, emphasized the strategic importance of this acquisition, stating, "This investment enhances our leadership position in Europe’s comprehensive spray-drying solutions market. The location of our Nottingham and Haverhill sites is strategically beneficial, enabling us to combine top-tier scientific expertise with strong production capabilities within a unified quality assurance system."
Additionally, this acquisition will complement Codis' existing large-scale spray-drying facility in Haverhill, UK. The Haverhill site is currently undergoing significant expansion with the installation of a new GEA Pharma-SD® PSD-4 commercial spray dryer, slated for validation in 2027. With both sites operating in close proximity, Codis anticipates a synergistic effect that will allow them to offer fully integrated services from formulation development to commercial scale production.
One of the main challenges in pharmaceutical development is the transition from formulation to commercial production, particularly for small molecule drug candidates that often suffer from low solubility. The spray-drying process utilized by Codis provides a critical solution to enhance bioavailability—a key consideration for many pharmaceutical developers. By merging formulation development with Good Manufacturing Practice (GMP) compliant production, Codis seeks to minimize risk while maximizing the potential of drug candidates.
As it continues to innovate within the pharmaceutical space, Codis remains committed to expanding its capabilities to better serve clients in health sectors, including nutraceuticals and over-the-counter medications. The Nottingham facility’s team will bring invaluable expertise, further enriching Codis' knowledge base and operational capacity.
In summary, the acquisition of Catalent’s Nottingham site represents Codis' strategic efforts to lead in integrated spray-drying solutions within Europe. By fostering innovation and ensuring compliance with necessary regulatory standards, Codis aims to deliver superior pharmaceutical solutions that can address the needs of the evolving healthcare landscape more effectively. With expansion plans already in motion, Codis is poised to not only enhance its operational capacity but also to redefine industry standards for quality and service in pharmaceutical manufacturing.
The Nottingham facility is well-regarded for its robust expertise in formulation development and scientific research, possessing over two decades of experience in providing successful spray-drying and oral solid dosage solutions. By integrating this facility into its operations, Codis aims to not only enhance its product offerings but also streamline its development-to-production processes, thereby positioning itself at the forefront of the rapidly evolving pharmaceutical landscape.
Nicolas Fortin, CEO of Codis, emphasized the strategic importance of this acquisition, stating, "This investment enhances our leadership position in Europe’s comprehensive spray-drying solutions market. The location of our Nottingham and Haverhill sites is strategically beneficial, enabling us to combine top-tier scientific expertise with strong production capabilities within a unified quality assurance system."
Additionally, this acquisition will complement Codis' existing large-scale spray-drying facility in Haverhill, UK. The Haverhill site is currently undergoing significant expansion with the installation of a new GEA Pharma-SD® PSD-4 commercial spray dryer, slated for validation in 2027. With both sites operating in close proximity, Codis anticipates a synergistic effect that will allow them to offer fully integrated services from formulation development to commercial scale production.
One of the main challenges in pharmaceutical development is the transition from formulation to commercial production, particularly for small molecule drug candidates that often suffer from low solubility. The spray-drying process utilized by Codis provides a critical solution to enhance bioavailability—a key consideration for many pharmaceutical developers. By merging formulation development with Good Manufacturing Practice (GMP) compliant production, Codis seeks to minimize risk while maximizing the potential of drug candidates.
As it continues to innovate within the pharmaceutical space, Codis remains committed to expanding its capabilities to better serve clients in health sectors, including nutraceuticals and over-the-counter medications. The Nottingham facility’s team will bring invaluable expertise, further enriching Codis' knowledge base and operational capacity.
In summary, the acquisition of Catalent’s Nottingham site represents Codis' strategic efforts to lead in integrated spray-drying solutions within Europe. By fostering innovation and ensuring compliance with necessary regulatory standards, Codis aims to deliver superior pharmaceutical solutions that can address the needs of the evolving healthcare landscape more effectively. With expansion plans already in motion, Codis is poised to not only enhance its operational capacity but also to redefine industry standards for quality and service in pharmaceutical manufacturing.
Topics Business Technology）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.